secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2022-11-28T23:59:59+00:00
Accession:  0000950170-22-025712
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus reports positive Phase 2 interim results for domvanalimab combo in NSCLC
------------------------------------------------------------------------------

- Fourth interim analysis of ARC-7 trial (n=133) shows domvanalimab-containing arms differentiate from zimberelimab monotherapy.
- Clinically meaningful improvements in objective response rate, PFS, and six-month landmark PFS observed.
- No unexpected safety signals; domvanalimab arms generally well tolerated with safety consistent with individual molecules.
- Detailed results to be presented at ASCO Monthly Plenary Series on December 20, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000095017022025712/0000950170-22-025712-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000095017022025712/rcus-20221128.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-025712

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer